KMT

KMT2A (Lysine Methyltransferase 2A), formerly known as MLL (Mixed-Lineage Leukemia), is a gene that plays a critical role in the regulation of gene expression through the modification of histones, which are proteins around which DNA is wound in the cell nucleus. The KMT2A gene is involved in the epigenetic control of gene activity, particularly during early development and hematopoiesis (the formation of blood cellular components). Mutations and translocations involving the KMT2A gene are associated with various types of leukemia and other hematologic malignancies.

Function

The KMT2A gene encodes a protein that is a member of the SET domain methyltransferase family. This protein specifically methylates the 4th lysine (K4) on histone H3, a modification known to be associated with actively transcribed genes. By modifying histones, KMT2A plays a crucial role in the regulation of gene expression, affecting processes such as cell cycle progression, differentiation, and the maintenance of genomic stability.

Clinical Significance

Alterations in the KMT2A gene, including chromosomal translocations and mutations, are implicated in the pathogenesis of several types of leukemia. The most common alteration is a translocation between chromosome 11q23, where KMT2A is located, and various other chromosomes. These translocations result in the fusion of the KMT2A gene with a partner gene, creating a fusion protein that contributes to leukemogenesis by dysregulating gene expression.

1. 1. 1. Acute Myeloid Leukemia (AML)

KMT2A rearrangements are particularly associated with acute myeloid leukemia (AML), where they are found in approximately 5-10% of cases. These rearrangements are often associated with a poor prognosis.

1. 1. 1. Acute Lymphoblastic Leukemia (ALL)

In acute lymphoblastic leukemia (ALL), KMT2A rearrangements are less common but are associated with a very aggressive disease course and a poor outcome, especially in adult patients.

1. 1. 1. Mixed-Lineage Leukemia

The term "mixed-lineage leukemia" is derived from the KMT2A gene's previous name (MLL) and refers to leukemias that show characteristics of both myeloid and lymphoid cells. These leukemias are particularly challenging to treat due to their aggressive nature.

Diagnosis and Treatment

The identification of KMT2A rearrangements is crucial for the diagnosis and risk stratification of leukemia patients. Techniques such as fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS) are commonly used to detect these genetic alterations.

Treatment strategies for leukemias with KMT2A alterations may include chemotherapy, targeted therapy, and stem cell transplantation. The development of targeted therapies that specifically inhibit the oncogenic activity of KMT2A fusion proteins is an area of active research.

Research Directions

Ongoing research aims to better understand the molecular mechanisms by which KMT2A alterations contribute to leukemogenesis and to develop more effective targeted therapies. The study of KMT2A also provides insights into the broader field of epigenetics and its role in cancer and development.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian